NCT02140281

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Ardelyx · Industry
• Sex: All
• Age: 18 Days – 50 Years
• Healthy volunteers: Accepted

Summary

A study to evaluate the effect of repeated oral doses of AZD1722 on the pharmacokinetics of Cefadroxil

Detailed description

A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Treatment A (cefadroxil alone)	A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
DRUG	Treatment B - AZD1722 followed by cefadroxil	15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil

Timeline

• Start date: 2014-05-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2014-05-16
• Last updated: 2015-09-22

Locations

1 site across 1 country: United States